ResMed
686 hedge funds and large institutions have $25.4B invested in ResMed in 2021 Q3 according to their latest regulatory filings, with 80 funds opening new positions, 234 increasing their positions, 256 reducing their positions, and 46 closing their positions.
74% more first-time investments, than exits
New positions opened: 80 | Existing positions closed: 46
9% more funds holding in top 10
Funds holding in top 10: 11 → 12 (+1)
6% more capital invested
Capital invested by funds: $23.9B → $25.4B (+$1.51B)
4% more funds holding
Funds holding: 661 → 686 (+25)
9% more call options, than puts
Call options by funds: $65.1M | Put options by funds: $59.6M
0.48% less ownership
Funds ownership: 66.65% → 66.17% (-0.48%)
9% less repeat investments, than reductions
Existing positions increased: 234 | Existing positions reduced: 256
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$97.2M |
| 2 |
Two Sigma Advisers
New York
|
+$76.4M |
| 3 |
Two Sigma Investments
New York
|
+$66.9M |
| 4 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$46.8M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$38.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$107M |
| 2 |
JP Morgan Chase
New York
|
-$68.2M |
| 3 |
Morgan Stanley
New York
|
-$60.6M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$57.7M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$57.3M |
RMD Hedge Fund Activity: Q3 2021 in Review
686 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in ResMed (RMD) for Q3 2021, worth a combined $25.4B — up 6.3% from $23.9B a quarter earlier.
Buyers outnumbered sellers: 80 funds opened new RMD positions and 46 closed out — a net gain of 34 holders — while 234 added to existing stakes and 256 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $97.2M. The largest seller was Baillie Gifford & Co, cutting an estimated $107M.
- 686 institutional investors held ResMed (RMD) as of Q3 2021, up from 661 in Q2 2021.
- Funds reported $25.4B of ResMed stock for Q3 2021, up 6.3% quarter-over-quarter.
- 80 funds opened new ResMed positions in Q3 2021 and 46 closed out, a net change of +34 holders.
- The largest ResMed buyer in Q3 2021 was Fidelity Investments, an estimated $97.2M added.
- The largest ResMed seller in Q3 2021 was Baillie Gifford & Co, an estimated $107M sold.
Based on aggregated 13F filings for Q3 2021.